Farnesoid X receptor
(FXR), a member of the nuclear receptor
superfamily,
plays an important role in maintaining or reversing metabolic homeostasis
during
the development of liver diseases. However, developing FXR modulators
to intervene in FXR-related diseases is still an unmet clinical need.
Therefore, it is significant to develop novel small-molecule agonists
for drug discovery targeting FXR. Through a high-throughput chemical
screen and follow-up biological validations, we first identified the
natural product Fargesone A (FA) as a potent and selective FXR agonist.
The limited, variable supply of FA from natural product isolation,
however, has impeded its biological exploration and potential drug
development. Accordingly, we have developed a biomimetic and scalable
total synthesis of FA in nine steps that provides a solution to the
supply of FA. Enabled by chemical synthesis, the in vivo efficacy of FA has been further investigated. The results showed
that FA alleviates hepatocyte lipid accumulation and cell death in
an FXR-dependent manner. Moreover, treatment of bile duct ligation
(BDL)-induced liver disorder with FA ameliorates pathological features
in mice. Therefore, our work lays the foundation to develop new small-molecule
FXR agonists as a potential
therapy for liver diseases.